ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Coronavirus

Takeda starts trials of 3 COVID drugs in US with Amgen and AbbVie

Alliance looks to test existing treatments' potential against coronavirus

An alliance of 20 partners including Takeda Pharmaceutical will test multiple drug candidates in the coming months.   © Reuters

TOKYO -- Takeda Pharmaceutical has begun clinical trials on three potential treatments for COVID-19 as part of a research and development team that includes U.S. peers Amgen and AbbVie Japan's biggest drugmaker said Tuesday.

The COVID R&D Alliance is recruiting up to 1,500 patients for the trials, which will take place in the U.S. over a few months.

If successful, applications would follow for approval to use these existing drugs to treat COVID-19. The effort comes amid an international search for drugs that can be repurposed to fight the pandemic.

The trials will examine the efficacy of Takeda's anti-inflammatory drug Firazyr in treating COVID-19 symptoms. Firazyr is prescribed to people with hereditary angioedema, a rare disease that causes swelling in the face and airways. The drug is expected to alleviate fluid buildup in the lungs of critically ill coronavirus patients.

The alliance also will test Amgen's psoriasis drug Otezla, along with cenicriviroc, which is used to treat liver disease. Both drugs are anticipated to suppress autoimmune responses in COVID-19 patients.

Formed in March, the COVID R&D Alliance has more than 20 members seeking to jointly investigate the efficacy of drugs in their portfolio in treating the disease, thereby saving time compared with conducting separate trials.

The U.S. Food and Drug Administration is also partner in the trials, as is Quantum Leap Healthcare Collaborative, a nonprofit set up by medical researchers and Silicon Valley entrepreneurs.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media